drugset / Trial / NCT00027599
APC8015 and Bevacizumab in Treating Patients With Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
Phase II trial to study the effectiveness of APC8015 combined with bevacizumab in treating patients who have undergone radiation therapy and/or surgery and who have progressive prostate cancer. Biological therapies such as APC8015 use different ways to stimulate the immune system and stop cancer cells from growing. Monoclonal antibodies such as bevacizumab can locate tumor cells and kill them without harming normal cells. Combining monoclonal antibody therapy with biological therapy may kill more cancer cells.
Timeline
- Start
- 2001-12
- Primary completion
- 2007-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Sipuleucel-T | Cell therapy | — | — |
| Subject | prostatic acid phosphatase-sargramostim fusion protein | Protein / enzyme biologic | — | — |
| Subject | therapeutic autologous dendritic cells | Vaccine | — | — |